Further, IL-10, a suppressive cytokine that dampens CD4+ T-cell expansion and function [75], was significantly lower in DCV2-treated groups (Figure 10E), suggesting that DCV2 more effectively counters immunosuppression within the tumor microenvironment. The gene discussed is CD4; the disease is neoplasm.